Literature DB >> 759882

Reduction in size of a pituitary tumor by bromocriptine therapy.

A M McGregor, M F Scanlon, K Hall, D B Cook, R Hall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 759882     DOI： 10.1056/NEJM197902083000606

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  19 in total

Review 1.  Medical treatment of pituitary adenomas: effects on tumor growth.

Authors:  A Liuzzi; P G Chiodini; D Dallabonzana; G Oppizzi; G G Verde
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

2.  Plasma prolactin in amenorrhoea, infertility, and other disorders: a retrospective study of 608 patients.

Authors:  P Skrabanek; D McDonald; E de Valera; O Lanigan; D Powell
Journal:  Ir J Med Sci       Date:  1980-06       Impact factor: 1.568

3.  Prolactinoma: a question of rational treatment.

Authors:  C R Edwards; C M Feek
Journal:  Br Med J (Clin Res Ed)       Date:  1981-12-12

4.  The 'Alice in Wonderland' experience. Ergot alkaloid therapy for prolactin-secreting pituitary tumors.

Authors:  R C Williams; C Sherman; M T Buckman
Journal:  West J Med       Date:  1983-03

5.  The management of prolactin-secreting pituitary tumors.

Authors:  S R George; G N Burrow
Journal:  J Endocrinol Invest       Date:  1981 Oct-Dec       Impact factor: 4.256

6.  Treatment of prolactin producing pituitary adenomas.

Authors:  R V Randall
Journal:  Trans Am Clin Climatol Assoc       Date:  1982

7.  Partial remission of hyperprolactinemic amenorrhea after bromocriptine-induced pregnancy.

Authors:  C Campagnoli; L Belforte; F Massara; C Peris; G M Molinatti
Journal:  J Endocrinol Invest       Date:  1981 Jan-Mar       Impact factor: 4.256

8.  Long-acting bromocriptine for the acute treatment of large macroprolactinomas.

Authors:  A Zarate; C Moran; R Miranda; M Loyo; M Medina; M E Fonseca
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

9.  Plasma testosterone levels of sexually functional and dysfunctional men.

Authors:  M F Schwartz; R C Kolodny; W H Masters
Journal:  Arch Sex Behav       Date:  1980-10

10.  Nerve growth factor suppresses the transforming phenotype of human prolactinomas.

Authors:  C Missale; F Boroni; M Losa; M Giovanelli; A Zanellato; R Dal Toso; A Balsari; P Spano
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.